The Cost-Effectiveness of Biologics for the Treatment of Rheumatoid Arthritis : A Systematic Review

Show full item record



Permalink

http://hdl.handle.net/10138/160267

Citation

Joensuu , J T , Huoponen , S , Aaltonen , K J , Konttinen , Y T , Nordstrom , D & Blom , M 2015 , ' The Cost-Effectiveness of Biologics for the Treatment of Rheumatoid Arthritis : A Systematic Review ' , PLoS One , vol. 10 , no. 3 , 0119683 . https://doi.org/10.1371/journal.pone.0119683

Title: The Cost-Effectiveness of Biologics for the Treatment of Rheumatoid Arthritis : A Systematic Review
Author: Joensuu, Jaana T.; Huoponen, Saara; Aaltonen, Kalle J.; Konttinen, Yrjo T.; Nordstrom, Dan; Blom, Marja
Contributor: University of Helsinki, Faculty of Pharmacy
University of Helsinki, Faculty of Pharmacy
University of Helsinki, Faculty of Pharmacy
University of Helsinki, Department of Medicine
University of Helsinki, Clinicum
University of Helsinki, Faculty of Pharmacy
Date: 2015-03-17
Language: eng
Number of pages: 27
Belongs to series: PLoS One
ISSN: 1932-6203
URI: http://hdl.handle.net/10138/160267
Abstract: Background and Objectives Economic evaluations provide information to aid the optimal utilization of limited healthcare resources. Costs of biologics for Rheumatoid arthritis (RA) are remarkably high, which makes these agents an important target for economic evaluations. This systematic review aims to identify existing studies examining the cost-effectiveness of biologics for RA, assess their quality and report their results systematically. Methods A literature search covering Medline, Scopus, Cochrane library, ACP Journal club and Web of Science was performed in March 2013. The cost-utility analyses (CUAs) of one or more available biological drugs for the treatment of RA in adults were included. Two independent investigators systematically collected information and assessed the quality of the studies. To enable the comparison of the results, all costs were converted to 2013 euro. Results Of the 4890 references found in the literature search, 41 CUAs were included in the current systematic review. While considering only direct costs, the incremental cost-effectiveness ratio (ICER) of the tumor necrosis factor inhibitors (TNFi) ranged from 39,000 to 1 273,000 (sic)/quality adjusted life year (QALY) gained in comparison to conventional disease-modifying antirheumatic drugs (cDMARDs) in cDMARD naive patients. Among patients with an insufficient response to cDMARDs, biologics were associated with ICERs ranging from 12,000 to 708,000 (sic)/QALY. Rituximab was found to be the most cost-effective alternative compared to other biologics among the patients with an insufficient response to TNFi. Conclusions When 35,000 (sic)/QALY is considered as a threshold for the ICER, TNFis do not seem to be cost-effective among cDMARD naive patients and patients with an insufficient response to cDMARDs. With thresholds of 50,000 to 100,000 (sic)/QALY biologics might be cost-effective among patients with an inadequate response to cDMARDs. Standardization of multiattribute utility instruments and a validated standard conversion method for missing utility measures would enable better comparison between CUAs.
Subject: TUMOR-NECROSIS-FACTOR
MODIFYING ANTIRHEUMATIC DRUGS
FACTOR-ALPHA INHIBITORS
EULAR RECOMMENDATIONS
TREATMENT STRATEGIES
ECONOMIC-EVALUATION
CLINICAL-PRACTICE
INADEQUATE RESPONSE
UTILITY ANALYSIS
SOUTHERN SWEDEN
317 Pharmacy
Rights:


Files in this item

Total number of downloads: Loading...

Files Size Format View
journal.pone.0119683.PDF 363.2Kb PDF View/Open

This item appears in the following Collection(s)

Show full item record